MSC treatment reduced the quantity of CD3+/IGF-1+ cells that had infiltrated into the brain from 11.20 ± 2.95 per view field in the ischemia group to 6.6 ± 1.28 in the MSC group (Figures 5(i)–5(l)). This evidence concerns the gene IGF1 and ischemia.